Lipoproteins for therapeutic delivery: recent advances and future opportunities

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Wilhelm S, Tavares AJ, Dai Q et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 1–12 (2016). • Severely criticizes nano-delivery approaches due to the low efficiency of payload delivery to tumor targets.
  Google Scholar
• 2 Lacko AG, Nair M, Prokai L, McConathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Exp. Opin. Drug Deliv. 4, 665–75 (2007).
  Medline CASGoogle Scholar
• 3 Segré D, Ben-Eli D, Deamer D, Lancet D. The lipid world. Origins Life Evol. Biospheres 31, 119–145 (2001).
  Medline CASGoogle Scholar
• 4 Deamer D. The first living systems: a bioenergetic perspective. Microbiol. Mol. Biol. Rev. 61, 239–261 (1997).
  Medline CASGoogle Scholar
• 5 Mulkidjanian A, Galperin M, Koonin E. Co-evolution of primordial membranes and membrane proteins. TrendsBiochem. Sci. 34, 206–215 (2009).
  Medline CASGoogle Scholar
• 6 Fredrickson DS. Phenotyping. On reaching base camp (1950–1975). Circulation 87(4 Suppl.), III1–15 (1993).
  Medline CASGoogle Scholar
• 7 Szostak JW, Bartel D, Luisi P. Synthesizing Life. Nature 409, 387–390 (2001).
  Medline CASGoogle Scholar
• 8 Barker W, Dayhoff M. Evolution of lipoproteins deduced from protein sequence data. Comp. Biochem. Physiol. Part B 57, 309–315 (1197).
  Google Scholar
• 9 Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug-delivery system in targeted chemotherapy. Int. J. Nanomed. 12, 8483–8493 (2017).
  Medline CASGoogle Scholar
• 10 Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials 156, 217–237 (2017).
  MedlineGoogle Scholar
• 11 Huff T, Jialal II. Physiology, cholesterol. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, USA (2017). www.ncbi.nlm.nih.gov/books/NBK470561.
  Google Scholar
• 12 Mateu L, Tardieu A, Luzzati V, Aggerbeck L, Scanu AM. On the structure of human serum low density lipoprotein. J. Mol. Biol. 70, 105–114 (1972).
  Medline CASGoogle Scholar
• 13 Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4(3), 193–205 (2005).
  Medline CASGoogle Scholar
• 14 Motulsky AG. The 1985 Nobel Prize in physiology or medicine. Science 231, 126–9 (1986).
  Medline CASGoogle Scholar
• 15 Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nat. Rev. Mol. Cell Biol. 11(10), 688–699 (2010).
  Medline CASGoogle Scholar
• 16 Simons K, Ikonen E. How cells handle cholesterol. Science 290, 1721–1726 (2000).
  Medline CASGoogle Scholar
• 17 Clendening JW, Pandyra A, Boutros PC et al. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl Acad. Sci. USA 107, 15051–15056 (2010).
  Medline CASGoogle Scholar
• 18 Cruz PM, Mo H, McConathy WJ et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front. pharmacol. 4, 119 (2013).
  MedlineGoogle Scholar
• 19 Hilvo M, Santiago ID, Gopalacharyulu P et al. Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. Cancer Res. 76(4), 796–804 (2016).
  Medline CASGoogle Scholar
• 20 Hirsch HA, Iliopoulos D, Joshi A et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17(4), 348–361 (2010).
  Medline CASGoogle Scholar
• 21 Niendorf A, Nagele H, Gerding D et al. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int. J. Cancer J. Int. du Cancer 61(4), 461–464 (1995).
  Medline CASGoogle Scholar
• 22 Muntoni S, Atzori L, Mereu R et al. Serum lipoproteins and cancer. Nutr. Metab. Cardiovasc. Dis. 19(3), 218–225 (2009).
  Medline CASGoogle Scholar
• 23 Moschovi M, Trimis G, Apostolakou F, Papassotiriou I, Tzortzatou-Stathopoulou F. 2004. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J. Pediatr. Hematol. Oncol. 26, 289–93 (2005).
  Google Scholar
• 24 Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int. J. Cancer 43, 875–879 (1989).
  Medline CASGoogle Scholar
• 25 Chajes V, Mahon M, Kostner GM. Influence of LDL oxidation on the proliferation of human breast cancer cells. Free Radic. Biol. Med. 20, 113–20 (1996).
  Medline CASGoogle Scholar
• 26 Counsell RE, Pohland RC. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. 25, 1115–20 (1982). • First article drawing attention to the favorable characteristics of lipoproteins as drug-delivery agents.
  Medline CASGoogle Scholar
• 27 Lacko AG, Sabnis NA, Nagarajan B, McConathy WJ. HDL as a drug and nucleic acid delivery vehicle. Front. Pharmacol. 6, 247 (2015).
  MedlineGoogle Scholar
• 28 Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano. 5(1), 42–57 (2011).
  Medline CASGoogle Scholar
• 29 Zhang X, Huang G. Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery. Drug Deliv. 24(Suppl. 1), 16–21 (2017).
  Medline CASGoogle Scholar
• 30 Thaxton CS, Rink JS, Naha PC, Cormode DP. Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv. Drug Deliv. Rev. 106(Pt A), 116–131 (2016). •• Major review, detailing the state of the art on the drug-delivery capabilities of lipoprotein-based formulations.
  Medline CASGoogle Scholar
• 31 Sabnis NA, Nair M, Israel M, McConathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomed. 7, 975–983 (2012).
  Medline CASGoogle Scholar
• 32 Sabnis N, Pratap S, Akopova I, Bowman WP, Lacko AG. Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front. Pediat. Oncol. 1, 1–10 (2013).
  MedlineGoogle Scholar
• 33 Rui M, Xin Y, Li R, Ge Y, Feng C, Xu X. Targeted biomimetic nanoparticles for synergistic combination chemotherapy of paclitaxel and doxorubicin. Mol. Pharm. 14, 107–123 (2017).
  Medline CASGoogle Scholar
• 34 Zhang X, Chen B. Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett. 298(1), 26–33 (2010).
  Medline CASGoogle Scholar
• 35 Shahzad MM, Mangala LS, Han HD et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4), 309–319 (2011). • One of the first accounts of efficient siRNA delivery to tumors.
  Medline CASGoogle Scholar
• 36 Ding Y, Wang W, Feng M et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33, 8893–905 (2012).
  Medline CASGoogle Scholar
• 37 McMahon KM, Thaxton CS. High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin. Drug Deliv. 231–47 (2014).
  MedlineGoogle Scholar
• 38 Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA 102(49), 17757–62 (2005).
  Medline CASGoogle Scholar
• 39 Mooberry LK, Nair M, Paranjape S et al. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target 18, 53–8 (2010). • First demonstration of drug delivery to cancer cells via the SR-B1 receptor.
  Medline CASGoogle Scholar
• 40 Lundberg B. Preparation of drug-low density lipoprotein complexes or delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. 47(15), 4105–4108 (1987).
  Medline CASGoogle Scholar
• 41 Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem. 5(2), 105–113 (1994).
  Medline CASGoogle Scholar
• 42 Almer G, Mangge H, Zimmer A, Prassl R. Lipoprotein-related and apolipoprotein-mediated delivery systems for drug targeting and imaging. Curr. Med. Chem. 22(31), 3631–3651 (2015).
  Medline CASGoogle Scholar
• 43 Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am. J. Obstet. Gynecol. 139(8), 877–885 (1981).
  Medline CASGoogle Scholar
• 44 Vitols S, Söderberg-Reid K, Masquelier M, Sjöström B, Peterson C. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug–lipoprotein complex. Br. J. Cancer. 62(5), 724–9 (1990).
  Medline CASGoogle Scholar
• 45 Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G. Ligand conjugated low density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129, 5798–5799 (2007).
  Medline CASGoogle Scholar
• 46 Corbin IR, Li H, Chen J et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8(6), 488–498 (2006).
  Medline CASGoogle Scholar
• 47 Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56, 1315–34 (2004).
  Medline CASGoogle Scholar
• 48 Ou W, Mulik RS, Anwar A, McDonald JG, He X, Corbin IR. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma. Free Radic. Biol. Med. 112, 597–607 (2017).
  Medline CASGoogle Scholar
• 49 Nikanjam M, Blakely EA, Bjornstad KA et al. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm. 328, 86–94 (2007).
  Medline CASGoogle Scholar
• 50 Baillie G, Owens MD, Halbert GW. A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. J. Lipid Res. 43, 69–73 (2002).
  Medline CASGoogle Scholar
• 51 Hayavi S, Halbert GW. Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture. Biotechnol. Prog. 21(4), 1262–8 (2005).
  Medline CASGoogle Scholar
• 52 Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. Circ. Res. 114, 143–56 (2014).
  Medline CASGoogle Scholar
• 53 Mooberry LK, Sabnis NA, Panchoo M et al. Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging. Front. Pharmacol. 7, 466 (2016).
  MedlineGoogle Scholar
• 54 Schörghofer D, Kinslechner K, Preitschopf A et al. The HDL receptor, SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod. Biol. Endocrinol. 13, 88 (2017).
  Google Scholar
• 55 Yuan B, Wu C, Wang X, Wang D, Liu H, Guo L et al. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer. Tumour Biol. 37, 3581–3588 (2016).
  Medline CASGoogle Scholar
• 56 Zheng Y, Liu Y, Jin H. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 3, 477–86 (2013).
  MedlineGoogle Scholar
• 57 Xu GH, Lou N, Shi HC et al. Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. BMC Cancer 18, 88 (2018).
  MedlineGoogle Scholar
• 58 Zhang ZH, Chen J, Ding LL et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3), 430–437 (2010).
  Medline CASGoogle Scholar
• 59 Yang S, Damiano MG, Zhang H et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl Acad. Sci. USA. 110(7), 2511–2516 (2013).
  Medline CASGoogle Scholar
• 60 Hovingh GK, Bochem AE, Kastelein JJ. Apolipoprotein A-I mimetic peptides. Curr. Opin. Lipidol. 21(6), 481–486 (2010). • Discusses the literature available on potential applicability of apolipoprotein A-I mimetics in therapeutics.
  Medline CASGoogle Scholar
• 61 Yang M, Chen J, Cao W et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide–phospholipid nanoscaffold. Nanomedicine (Lond.) 6(4), 631–641 (2011).
  Medline CASGoogle Scholar
• 62 Anantharamaiah GM, Jones JL, Brouillette CG et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260(18), 10248–10255 (1985).
  Medline CASGoogle Scholar
• 63 Zhang Z, Chen J, Ding L et al. HDL mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3), 430–437 (2010). • One of the first assemblies using apolipoprotein mimetics for tumor targeting.
  Medline CASGoogle Scholar
• 64 Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-density lipoproteins (HDL) – nature's multi-functional nanoparticles. ACS Nano. 10(3), 3015–3041 (2016). •• Important recent article on application of HDL nanodiscs as potential delivery vehicles of cancer immunotherapy.
  Medline CASGoogle Scholar
• 65 Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44(10), 1105–1113 (2011).
  Medline CASGoogle Scholar
• 66 McMahon KM, Foit L, Angeloni NL et al. Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat Res. 166, 129–150 (2015).
  Medline CASGoogle Scholar
• 67 Foit L, Giles FJ, Gordon LI et al. Synthetic high-density lipoprotein-like nanoparticles for cancer therapy. Expert Rev. Anticancer Ther. 15, 27–34 (2015).
  Medline CASGoogle Scholar
• 68 Wang Y, Wang C, Ding Y et al. Biomimetic HDL nanoparticle mediated tumor targeted delivery of indocyanine green for enhanced photodynamic therapy. Colloids Surf. Biointerfaces 148, 533–540 (2016).
  Medline CASGoogle Scholar
• 69 Shah S, Chib R, Raut S, Bermudez J et al. Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent. J. Photochem. Photobiol. B 155, 60–65 (2016).
  Medline CASGoogle Scholar
• 70 Pérez-Medina C, Tang J, Abdel-Atti D et al. PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles. J. Nucl. Med. 56, 1272–1277 (2015).
  Medline CASGoogle Scholar
• 71 Sabnis S, Sabnis N, Raut S, Lacko AG. Superparamagnetic reconstituted high-density lipoprotein nanocarriers for magnetically guided drug delivery. Int. J. Nanomedicine 12, 1453–1464 (2017).
  Medline CASGoogle Scholar
• 72 Xiong F, Sabnis N, Sirsi SR et al. Ultrasound-stimulated drug delivery using therapeutic reconstituted high-density lipoprotein nanoparticles. Nanotheranostics 1, 440–449 (2017).
  MedlineGoogle Scholar
• 73 Lee H, Kim SI, Shin D et al. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. Biochem. Biophys. Res. Commun. 378, 192–196 (2009).
  Medline CASGoogle Scholar
• 74 Vickers KC, Palmisano BT, Shoucri BM et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433 (2011).
  Medline CASGoogle Scholar
• 75 Wagner J, Riwanto M, Besler C et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler. Thromb. Vasc. Biol. 33, 1392–1400 (2013).
  Medline CASGoogle Scholar
• 76 Tabet F, Vickers KC, Ceusta-Torres LF et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nature Comm. 5, 3292 (2014).
  MedlineGoogle Scholar
• 77 Coffey AR, Smallwood TL, Albright J et al. Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDLcholesterol in murine diet-induced dyslipidemia. Physiol. Genomics 49(11), 618–629 (2017).
  Medline CASGoogle Scholar
• 78 McMahon KM, Mutharasan RK, Tripathy S et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano. Lett. 11, 1208–1214 (2011).
  Medline CASGoogle Scholar
• 79 Tripathy S, Vinokour E, McMahon KM et al. High-density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part. Syst. Charact. 31, 1141–1150 (2014).
  Medline CASGoogle Scholar
• 80 Rink JS, Yang S, Cen O et al. Scavenger receptor type B1 is essential for high density lipoprotein nanoparticle inducedB-cell lymphoma cell death. Blood 126, 2756 (2015).
  Google Scholar
• 81 Kannel WB, Dawber TR, Friedman GD et al. Risk factors in coronary heart disease. An evaluation of serveral serum lipids as predictors of coronary heart disease; the Framingham Study. Ann. Intern. Med. 61, 888–899 (1964).
  Medline CASGoogle Scholar
• 82 Ameli S, Hultgardh-Nilsson A, Cercek B et al. Recombinant apolipoprotein A-I Milano induces intimal thickening after balloon injury in hypercholesterolemic rebbits. Circulation 90, 1935–1941 (1994).
  Medline CASGoogle Scholar
• 83 Shah PK, Yano J, Reyes O et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 103, 3047–3050 (2001).
  Medline CASGoogle Scholar
• 84 Soma MR, Donetti E, Parolini C et al. Recombinant apolipoprotein A-I_Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76, 405–411 (1995).
  Medline CASGoogle Scholar
• 85 Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
  Medline CASGoogle Scholar
• 86 Tardif JC, Gregoire J, L'Allier PL et al. Effects of reconstituted high-denisty lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297(15), 1675–1682 (2007).
  MedlineGoogle Scholar
• 87 Sacks FM, Rudel LL, Conner A et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J. Lipid Res. 50, 894–907 (2009).
  Medline CASGoogle Scholar
• 88 Waksman R, Torguson R, Kent KM et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 55(24), 2727–2735 (2010).
  MedlineGoogle Scholar
• 89 Andrews J, Janssean A, Nguyen T et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc. Diagn. Ther. 7(1), 45–51 (2017).
  MedlineGoogle Scholar
• 90 Study shows no reduction in plaque with synthetic HDL-C injection. www.acc.org/latest-in-cardiology/articles/2017/03/13/17/44/sat-8am-carat-effect-of-serial-infusions-of-cer-001-on-cad-acc-2017.
  Google Scholar
• 91 Oda MM, Hargreaves P, Beckstead JA et al. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J. Lipid Res. 47(2), 260–267 (2006).
  Medline CASGoogle Scholar
• 92 Redmond KA, Nguyen TS, Ryan RO. All-trans retinoic acid nanodisks. Int. J. Pharm. 339(1–2), 246–250 (2007).
  Medline CASGoogle Scholar
• 93 Ghosh M, Singh ATK, Xu W et al. Curcumin nanodisks: formulation and characterization. Nanomedicine 7(2), 162–167 (2011).
  Medline CASGoogle Scholar
• 94 Singh ATK, Ghosh M, Forte TM et al. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leuk. Lymphoma 52(8), 1537–1543 (2011).
  Medline CASGoogle Scholar
• 95 Ghosh M, Ryan RO. ApoE enhances nanodisk-mediated curcumin delivery to glioblastoma multiforme cells. Nanomedicine 9(6), 763–771 (2014).
  Medline CASGoogle Scholar
• 96 Song Q, Huang M, Yao L et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. ACS Nano. 8(3), 2345–2359 (2014).
  Medline CASGoogle Scholar
• 97 Song Q, Song H, Xu J et al. Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery. Mol. Pharmaceutics 13, 3976–3987 (2016).
  Medline CASGoogle Scholar
• 98 Shah PK. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein. Am. J. Cardiol. 100(11A), S62–67 (2007).
  MedlineGoogle Scholar
• 99 Segrest JP, Jones MK, De Loof H et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 33, 141–66 (1992).
  Medline CASGoogle Scholar
• 100 Ryan RO, Forte TM, Oda MN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif. 27, 98–103 (2003).
  Medline CASGoogle Scholar
• 101 Pyle LE, Fidge NH, Barton PA et al. Production of mature human apolipoprotein A-I in a baculovirus-insect cell system: propeptide is not essential for intracellular processing but may assist rapid secretion. Anal. Biochem. 253, 253–8 (1997).
  Medline CASGoogle Scholar
• 102 Narasimhan Janakiraman V, Noubhani A et al. High yield of recombinant human apolipoprotein A-I expressed in Pichia pastoris by using mixed-mode chromatography. Biotechnol. J. 11, 117–26 (2016).
  Medline CASGoogle Scholar
• 103 Nykiforuk CL, Shen Y, Murray EW et al. Expression and recovery of biologically active recombinant apolipoprotein AI(Milano) from transgenic safflower (Carthamus tinctorius) seeds. Plant Biotechnol. J. 9, 250–63 (2011).
  Medline CASGoogle Scholar
• 104 Schmidt HH, Genschel J, Haas R et al. Expression and purification of recombinant human apolipoprotein A-I in Chinese hamster ovary cells. Protein Expr. Purif. 10, 226–36 (1997).
  Medline CASGoogle Scholar
• 105 Caparon MH, Rust KJ, Hunter AK et al. Integrated solution to purification challenges in the manufacture of a soluble recombinant protein in E. coli. Biotechnol. Bioeng. 105, 239–49 (2010).
  Medline CASGoogle Scholar
• 106 Rosenson RS, Brewer HB Jr, Davidson WS et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125, 1905–19 (2012).
  MedlineGoogle Scholar
• 107 Dasseux J-L, Ackermann R: US9187551 (2015).
  Google Scholar
• 108 Navab M, Anantharamaiah GM, Reddy ST et al. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 5, 1325–31 (2005).
  Google Scholar
• 109 Gomaraschi M, Calabresi L, Rossoni G et al. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324, 776–783 (2008).
  Medline CASGoogle Scholar
• 110 Van Lenten BJ, Wagner AC, Anantharamaiah GM et al. Apolipoprotein A-I mimetic peptides. Curr. Atheroscler. Rep. 11, 52–57 (2009).
  Medline CASGoogle Scholar
• 111 Neyen C, Mukhopadhyay S, Gordon S, Hagemann T. An apolipoprotein A-I mimetic targets scavenger receptor A on tumor-associated macrophages: A prospective anticancer treatment? Oncoimmunology 2, e24461 (2013).
  MedlineGoogle Scholar
• 112 Lin Q, Chen J, Jin H et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 7, 1813–25 (2012).
  Medline CASGoogle Scholar
• 113 Brinkman N, Bigler D, Bolli R, Foertsch V: US8962802 (2015).
  Google Scholar
• 114 Vucica Y, Warren GL: US9125943 (2015).
  Google Scholar
• 115 Nanjee MN, Crouse JR, King JM et al. Effects of intravenous infusion of lipid-free ApoA-I in humans. Arterioscler. Thromb. Vasc. Biol. 16, 1203–14 (1996).
  Medline CASGoogle Scholar
• 116 Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19, 979–89 (1999).
  Medline CASGoogle Scholar
• 117 www.csl.com/news/20171205-csl112-phase-3-clinical-trial. CSL Limited, Melbourne, Australia.
  Google Scholar
• 118 www.themedicinescompany.com/investors/news/medicines-company-discontinues-development-mdco-216-its-investigational-cholesterol. The Medicines Company, Parsippany, NJ.
  Google Scholar
• 119 Keyserling CH, Barbaras R, Benghozi R et al. Development of CER-001: preclinical dose selection through to Phase I clinical findings. Clin. Drug Investig. 37, 483–491 (2017). • First successful attempt to produce recombinant apolipoprotein A-I on an industrial scale for clinical applications.
  Medline CASGoogle Scholar
• 120 Kootte RS, Smits LP, van der Valk FM et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J. Lipid Res. 56, 703–12 (2015).
  Medline CASGoogle Scholar
• 121 www.cerenis.com/images/pdfs/CP_cerenis_dernier_patient_tango_ENG.pdf. Cerenis Therapeutics, Labège, France.
  Google Scholar